

# Stefano Sainas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5237/publications.pdf>

Version: 2024-02-01

24  
papers

504  
citations

623734

14  
h-index

677142

22  
g-index

27  
all docs

27  
docs citations

27  
times ranked

590  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 86-105.	1.6	61
2	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- <i>c</i> ]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6034-6055.	6.4	57
3	Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111681.	5.5	56
4	Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds. <i>European Journal of Medicinal Chemistry</i> , 2017, 129, 287-302.	5.5	46
5	Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches. <i>MedChemComm</i> , 2015, 6, 1285-1292.	3.4	40
6	N-Acetyl-3-aminopyrazoles block the non-canonical NF- $\kappa$ B cascade by selectively inhibiting NIK. <i>MedChemComm</i> , 2018, 9, 963-968.	3.4	27
7	4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF- $\kappa$ B cascade. <i>MedChemComm</i> , 2017, 8, 1850-1855.	3.4	23
8	Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 266-280.	5.5	23
9	The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1003.	3.7	21
10	Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication. <i>Antiviral Research</i> , 2021, 189, 105057.	4.1	21
11	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- <i>c</i> ]pyridine Scaffold: SAR of the Biphenyl Moiety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5404-5428.	6.4	19
12	Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4467-4482.	6.4	18
13	The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses. <i>Microorganisms</i> , 2021, 9, 1731.	3.6	16
14	Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin. <i>Annual Reports in Medicinal Chemistry</i> , 2018, 51, 1-38.	0.9	14
15	Regioselective N-Alkylation of Ethyl 4-Benzyloxy-1,2,3-triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres. <i>Journal of Heterocyclic Chemistry</i> , 2019, 56, 501-519.	2.6	14
16	Hydroxyazoles as acid isosteres and their drug design applications—Part 1: Monocyclic systems. <i>Advances in Heterocyclic Chemistry</i> , 2021, 134, 185-272.	1.7	10
17	A New NF- $\kappa$ B Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats. <i>Brain Sciences</i> , 2022, 12, 35.	2.3	10
18	Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems. <i>Advances in Heterocyclic Chemistry</i> , 2021, , 273-311.	1.7	9

#	ARTICLE	IF	CITATIONS
19	DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents. <i>Drugs of the Future</i> , 2018, 43, 0823.	0.1	7
20	New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114366.	5.5	7
21	Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study. <i>Molecules</i> , 2022, 27, 3660.	3.8	3
22	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	1
23	AML-201: Synthetic Lethality in Acute Myeloid Leukemia: A Focus on Dihydroorotate Dehydrogenase Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S190.	0.4	0
24	Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3942-3942.	1.4	0